BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (November 2014)
28 slides from BioSpecifics Technologies's investor presentation, Nov 13, 2014
Slide 1: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE a 5 BioSpecifics November 2014
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”
Slide 3: Corporate Overview
Corporate Overview BioSpecifics is a profitable, commercial-stage biopharma company maximizing the potential of collagenase clostridium histolyticum or CCH (XIAFLEX®) for multiple commercial and clinical indications XIAFLEX is marketed in the U.S. by strategic partner, Auxilium Pharmaceuticals for D
Slide 4: Vast Therapeutic Potential of CCH
Vast Therapeutic Potential of CCH CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications: Dupuytren’s contracture* Froze
Slide 5: Marketed Indications for XIAFLEX
Marketed Indications for XIAFLEX Marketed * Dupuytren’s Decision on approval in Japan expected in mid-2015 Contracture Peyronie’s Decision on approval in EU expected in 1Q15 Disease
Slide 6: Commercial Success for XIAFLEX
Commercial Success for XIAFLEX Impressive Growth In Both Indications Total XIAFLEX revenues up 118% in 3Q14 over 3Q13 XIAFLEX U.S. net revenues for both indications were $34.6M over $15.9M in 3Q13, a 118% increase U.S. XIAFLEX revenues up 31% in 3Q14 over 2Q14 Est. 5,863 vials sold in 3Q14 for Dupuy
Slide 7: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand causing one or Definition and more fingers to contract toward the palm Key Complications Limits range of motion of the fingers often resulting in physical disability and impaired quality of life First and Only FDA- and EMA-
Slide 8: XIAFLEX Label Expansion
XIAFLEX Label Expansion sBLA Approved in October 2014 Expanded label allows for treatment of up to two Dupuytren’s contracture joints in the same hand during a single office visit SDI Health LLC estimates 35 to 40% of annual Dupuytren’s contracture surgeries in U.S. are performed to treat two or mor
Slide 9: Dupuytren's Contracture Commercial Opportunity
Dupuytren’s Contracture Commercial Opportunity Focus on Consistent U.S. Sales Growth Expansion in New Markets and Patient Subpopulations 300K patients diagnosed annually 32% market share YTD among all procedures Good sales momentum by Sobi within European markets Asahi Kasei submitted regulatory app
Slide 10: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease Definition & Key Complications First and Only FDA- Approved PD Treatment Pre-treatment: Excess of inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Pain with erection, penile shortening, indentations, erectile dysf
Slide 11: Peyronie's Disease Commercial Opportunity
Peyronie’s Disease Commercial Opportunity 95K patients* diagnosed in 2013 but believed to be U.S. Market underdiagnosed Opportunity Up to eight injections (four treatment cycles of two injections) in-office Auxilium Advantage™ - assists patients and providers in accessing XIAFLEX Providers: facilita
Slide 12: Commercial Progress
Commercial Progress Focused, disciplined initial product rollout 5,000-6,500 patients receive invasive treatment for Peyronie’s disease each year (plication, grafting, prosthesis surgery or verapamil injections) ~400 urologists account for 90% of PD surgeries REMS certification of urologists 1,450 T
Slide 13: Commercial Progress (Cont.)
Commercial Progress (Cont.) Reimbursement approval by payers (Auxilium Advantage) All eight Medicare beneficiaries confirmed coverage at policy level; 29 major commercial health plans have approved patients for treatment Listed as 'medically necessary’ in Clinical Policy Bulletin, when administered
Slide 14: XIAFLEX Pipeline Programs
XIAFLEX Pipeline Programs ats] recinal| Pnes | rasa [raves | Marte pozen e Top-line data in 1Q15 Canine Auxilium to determine development plan Lipoma * Human Complete enrollment in Phase 2 in 1Q15 Lipoma Cellulite Initiation of Phase 2b in 2Q15 *Uterine CITT Fibroids suitles *BioSpecifics-managed de
Slide 15: CCH for Lipomas
CCH for Lipomas Clinical Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges Benson under the skin Potential to be No FDA-approved pharmaceutical therapies available Only Approved Nonsurgical Therapy Surgery not practical for patients with mu
Slide 16: Positive Phase Clinical Trial Results in Humans Reported in January 2014
Positive Phase 2 Clinical Trial Results in Humans Reported in January 2014 Open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas showed: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combin
Slide 17: CCH for Lipomas in Canines
CCH for Lipomas in Canines Auxilium to Manage Development Program Key Complications Potential to be Only Approved Nonsurgical Therapy U.S. Market Opportunity $500K Opt-In Payment to BioSpecifics Encapsulated deposits of benign fatty tumors can cause seriously restrict motion in older dogs Most frequ
Slide 18: Opt-In Decision Based on Phase 2 Canine Trial
Opt-In Decision Based on Chien-804: Encouraging Placebo-Controlled, Phase 2 CCH Trial Randomized trial conducted in canines with benign subcutaneous lipomas. Study did not meet primary endpoint but demonstrated benefit in secondary measures: Responder analysis: Visible surface area as measured by ca
Slide 19: CCH for Uterine Fibroids
CCH for Uterine Fibroids New Study Results Reported in October 2014 Benign tumors E Te08 Definition & Pain, decreased fertility, H = Key Complications miscarriage, heavy menstrual 5 ae bleeding and frequent urination ae =e ; arene bso Potential to be pose omer a - er q00 025 050 400 200 - ysterectom
Slide 20: CCH for Frozen Shoulder Syndrome
CCH for Frozen Shoulder Syndrome Top-line Data from Phase 2b Study Expected in 1Q15 Definition and Key Complications Potential to be Only Approved Nonsurgical Therapy Market Opportunity Top-line Data from Phase 2b Study Expected in 1Q15 Source: Auxilium Pharmaceuticals, In. Inflammation and thickeni
Slide 21: Statistically Significant CCH Dose Response in Phase 2a Study
Statistically Significant CCH Dose Response in Phase 2a Study 2 3 t 1 Statistically significant improvements in oO valscum Mf | * sonar ‘both the 0.58 mg(1ml) and 0.58 350 to Exercise Cohor 1 Shoulder Abduction mg(2mL) cohorts over baseline scores a External Rotation vs. the exercise-only group: Hie
Slide 22: CCH for Cellulite
CCH for Cellulite Positive Phase 2a Top-line Results Reported in 3Q14 Skin dimpling as a result of collagen fibrous septae held in an Definition irregular pattern under the skin, occurring mainly on the buttocks, lower limbs, and abdomen de eee « Affects 85-98% of women (est.) and rarely in men ppor
Slide 23: CCH for Cellulite
CCH for Cellulite Initiation of Phase 2b Study Expected in 2Q15 Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with trea
Slide 24: Auxilium Partnership for Development and Commercialization of CCH
Auxilium Partnership for Development and Commercialization of CCH >$48M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Auxilium Opt-In Rights Milestone Payments. from AUXL Partnerships $48M received in licensing, sublicensing, milestone, COGS, and royalty payments as of Sep
Slide 25: Corporate Highlights
Corporate Highlights Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in U.S. until 2017; Drug p
Slide 26: Consistently Profitable Annually
Consistently Profitable Annually 3Q14 Financial Highlights For the quarter For the year ended ended 09/30/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments $s 17,500,003 $ 12,591,825 Income Statement Revenues $ 4,012,787 $ 14,467,240 Other income 8,121 26,202 Costs and
Slide 27: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Upcoming Milestones *Human Lipomas O Complete enrollment in Phase 2 placebo-controlled opt-in trial in 1Q15 eae Q Auxilium to determine development path Seen O Ongoing pre-clinical studies; refine development plan puperen Q Decision on approval by PMDA in Japan expect
Slide 28: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE ridium histolticUM, ss = November 2014
Biospecifics Technologies — Investor Presentation (November 2014) on 6ix